Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the
 frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to
 determine whether treatment with sitagliptin is effective in maintaining blood sugar control
 in patients with type 2 diabetes (T2D).
The purpose of this study is to determine whether treatment with sitagliptin reduces the
 frequency and severity of high blood sugar (hyperglycemia) and the need for continuous
 intravenous insulin infusion (CII) in the intensive care unit (ICU) in patients with type 2
 diabetes (T2D) undergoing coronary artery bypass graft (CABG) surgery. In addition, the study
 seeks to determine whether treatment with sitagliptin is effective in maintaining glycemic
 control and in preventing the need for subcutaneous (SC) insulin therapy in patients with T2D
 during the transition from intensive care unit (ICU) to regular floor in cardiac surgery
 patients with T2D.
Inclusion Criteria:

 -  The ability to provide informed consent

 -  Ages 18 to 80 years old

 -  Male or female

 -  Scheduled to undergo cardiac surgery

 -  Type 2 Diabetes treated with diet, oral agents,

 Exclusion Criteria:

 -  Severely impaired kidney function (glomeruler filtration rate (GFR ) less than 30
 ml/min)

 -  Clinically significant liver failure

 -  Imminent risk of death (brain death or cardiac standstill)

 -  Gastrointestinal obstruction or adynamic ileus

 -  Expected to require gastrointestinal suction

 -  Clinically relevant pancreatic or gallbladder disease

 -  Using oral or injectable corticosteroid

 -  Mental condition rendering the subject unable to understand the nature, scope, and
 possible consequences of the study

 -  Female subjects are pregnant or breast feeding at time of enrollment into the study